全球胰臟外分泌功能不全市场规模、份额、趋势和成长分析报告（2026-2034年）

预计外分泌胰臟功能不全的市场规模将从 2025 年的 36.9 亿美元成长到 2034 年的 62.3 亿美元，2026 年至 2034 年的复合年增长率为 5.99%。

受胃肠道和胰臟疾病日益普遍的推动，全球外分泌性胰臟功能不全市场正稳定成长。外分泌性胰臟功能不全是指胰臟无法产生足够的消化酶，导致营养吸收不足。人们对胃肠道健康的日益重视以及诊断能力的提升，促使更多患者寻求治疗，从而推动了市场成长。

推动该市场发展的主要因素是慢性胰臟炎、囊肿纤维化和胰臟癌等疾病发生率的上升。这些疾病通常会导致酵素缺乏，需要进行酵素替代疗法。製药公司也致力于开发更有效的胰酶替代疗法，这进一步促进了市场成长。

未来几年，随着医疗体係日益重视早期诊断和治疗方法，市场预计将持续成长。製剂技术的进步以及发展中地区医疗服务可近性的提高也将推动市场成长。此外，旨在改善消化酵素疗法的持续临床研究将为外分泌性胰臟功能不全的治疗创造新的机会。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章：全球外分泌性胰臟功能不全市场：依治疗方式划分

• 市场分析、洞察与预测
• 营养管理
• 胰酵素替代疗法（PERT）

第五章：全球外分泌性胰臟功能不全市场：依药物类型划分

• 市场分析、洞察与预测
• 克瑞翁
• Zenpep
• 庞克种族
• Viokace
• 其他药物类型

第六章：全球外分泌性胰臟功能不全市场：依症状划分

• 市场分析、洞察与预测
• 腹痛
• 便秘
• 腹泻
• 脂肪泻
• 减肥
• 其他症状

第七章 全球外分泌胰臟功能不全市场：依通路划分

• 市场分析、洞察与预测
• 医院药房
• 零售药房
• 网路药房

第八章 全球外分泌胰臟功能不全市场：依地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第九章 竞争情势

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第十章：公司简介

• 主要公司的市占率分析
• 公司简介
  • Abbott Laboratories
  • AbbVie
  • Digestive Care
  • Essential Pharma
  • Nestle
  • Nordmark Pharma
  • Sun Pharmaceutical Industries
  • Viatris
  • Vivus
  • Zentiva Pharma UK

The Exocrine Pancreatic Insufficiency Market size is expected to reach USD 6.23 Billion in 2034 from USD 3.69 Billion (2025) growing at a CAGR of 5.99% during 2026-2034.

The global exocrine pancreatic insufficiency market is growing steadily due to the increasing prevalence of digestive disorders and pancreatic diseases. Exocrine pancreatic insufficiency occurs when the pancreas does not produce enough digestive enzymes, leading to poor nutrient absorption. Rising awareness about gastrointestinal health and improved diagnostic capabilities are encouraging more patients to seek treatment, contributing to market growth.

A key driver of this market is the increasing incidence of conditions such as chronic pancreatitis, cystic fibrosis, and pancreatic cancer. These diseases often result in enzyme deficiencies that require enzyme replacement therapies. Pharmaceutical companies are also focusing on developing more effective pancreatic enzyme replacement treatments, which is further boosting the market.

In the coming years, the market is expected to expand as healthcare systems focus more on early diagnosis and improved treatment options. Advancements in drug formulations and growing access to healthcare services in developing regions will likely support market expansion. Additionally, ongoing clinical research aimed at improving digestive enzyme therapies will create new opportunities in the exocrine pancreatic insufficiency treatment landscape.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Treatment

• Nutritional Management
• Pancreatic Enzyme Replacement Therapy (PERT)

By Drug Type

• Creon
• Zenpep
• Pancreaze
• Viokace
• Other Drug Types

By Symptom

• Abdominal Pain
• Constipation
• Diarrhea
• Fatty Stools
• Weight Loss
• Other Symptoms

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

COMPANIES PROFILED

• Abbott Laboratories, AbbVie, Digestive Care, Essential Pharma, Nestle, Nordmark Pharma, Sun Pharmaceutical Industries, Viatris, Vivus, Zentiva Pharma UK
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY MARKET: BY TREATMENT 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Treatment
• 4.2. Nutritional Management Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Pancreatic Enzyme Replacement Therapy (PERT) Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY MARKET: BY DRUG TYPE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Drug Type
• 5.2. Creon Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Zenpep Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Pancreaze Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Viokace Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Other Drug Types Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY MARKET: BY SYMPTOM 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Symptom
• 6.2. Abdominal Pain Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Constipation Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Diarrhea Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Fatty Stools Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.6. Weight Loss Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.7. Other Symptoms Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Distribution Channel
• 7.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY MARKET: BY REGION 2022-2034 (USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Treatment
  • 8.2.2 By Drug Type
  • 8.2.3 By Symptom
  • 8.2.4 By Distribution Channel
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Treatment
  • 8.3.2 By Drug Type
  • 8.3.3 By Symptom
  • 8.3.4 By Distribution Channel
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Treatment
  • 8.4.2 By Drug Type
  • 8.4.3 By Symptom
  • 8.4.4 By Distribution Channel
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Treatment
  • 8.5.2 By Drug Type
  • 8.5.3 By Symptom
  • 8.5.4 By Distribution Channel
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Treatment
  • 8.6.2 By Drug Type
  • 8.6.3 By Symptom
  • 8.6.4 By Distribution Channel
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Abbott Laboratories
  • 10.2.2 AbbVie
  • 10.2.3 Digestive Care
  • 10.2.4 Essential Pharma
  • 10.2.5 Nestle
  • 10.2.6 Nordmark Pharma
  • 10.2.7 Sun Pharmaceutical Industries
  • 10.2.8 Viatris
  • 10.2.9 Vivus
  • 10.2.10 Zentiva Pharma UK